Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Frontiers in Medicine

Xin Wang¹  Fang Wang¹  Gang Liu¹  Shuang Gao¹  Li-qiang Meng¹  Zhao Cui¹  Xu-yang Cheng¹  Fu-de Zhou¹  Yi-miao Zhang¹  Ming-hui Zhao² 

[1] Renal Division, Peking University First Hospital, Beijing, China;Institute of Nephrology, Peking University, Beijing, China;Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China;Key Laboratory of Chronic Kidney Disease (CKD) Prevention and Treatment, Ministry of Education of China, Beijing, China;Renal Division, Peking University First Hospital, Beijing, China;Institute of Nephrology, Peking University, Beijing, China;Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China;Key Laboratory of Chronic Kidney Disease (CKD) Prevention and Treatment, Ministry of Education of China, Beijing, China;Peking-Tsinghua Center for Life Sciences, Beijing, China;

关键词: primary membranous nephropathy;    CD20 monoclonal antibody;    rituximab;    anti-PLA2R antibody;    first line treatment;   

DOI  :  10.3389/fmed.2021.663680

来源: Frontiers

【 授权许可】

CC BY